T3 PHARMACEUTICALS

t3-pharmaceuticals-logo

The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.

#SimilarOrganizations #People #Financial #Website #More

T3 PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Life Science Therapeutics

Founded:
2015-01-01

Address:
Basel, Basel-Stadt, Switzerland

Country:
Switzerland

Website Url:
http://www.t3pharma.com

Total Employee:
1+

Status:
Active

Contact:
+410612672074

Email Addresses:
[email protected]

Total Funding:
37 M CHF

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving SSL By Default Google Maps LetsEncrypt Apple Mobile Web App Capable QUIC Google No Translate TYPO3


Similar Organizations

bright-peak-therapeutics-logo

Bright Peak Therapeutics

Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.

cellics-therapeutics-logo

Cellics Therapeutics

Cellics is committed to saving lives and improving patientsโ€™ health using innovative biomimetic nanomedicines.

gfbiochemicals-logo

GFBiochemicals

GFBiochemicals company to produce levulinic acid at commercial scale directly from biomass.

mogrify-logo

Mogrify

Mogrifyยฎ will transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies.

okomera-logo

Okomera

Okomera is a biotech start-up that accelerates access to improved, precision-based cancer therapies.

polymateria-logo

Polymateria

Polymateria is a startup advancing science to help nature deal with plastic pollution.

proto-axiom-logo

Proto Axiom

Proto Axiom on-shores pre-clinical R&D expertise to bridge the gap.

qubit-pharmaceuticals-logo

Qubit Pharmaceuticals

Qubit Pharmaceuticals is an EIT Health Headstart laureate and is incubated at Paris Biotech Santรฉ.

Current Employees Featured

simon-j-ittig_image

Simon J. Ittig
Simon J. Ittig CEO and Co-founder @ T3 Pharmaceuticals
CEO and Co-founder
2015-05-01

christoph-kasper_image

Christoph Kasper
Christoph Kasper CSO and Co-founder @ T3 Pharmaceuticals
CSO and Co-founder
2015-05-01

Founder


christoph-kasper_image

Christoph Kasper

simon-j-ittig_image

Simon J. Ittig

Investors List

innosuisse_image

Innosuisse

Innosuisse investment in Grant - T3 Pharmaceuticals

swiss-economic-award_image

Swiss Economic Award

Swiss Economic Award investment in Grant - T3 Pharmaceuticals

Reference-Capital-SA_image

Reference Capital SA

Reference Capital SA investment in Series C - T3 Pharmaceuticals

wille-finance_image

Wille Finance

Wille Finance investment in Series C - T3 Pharmaceuticals

boehringer-ingelheim-venture-fund_image

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund investment in Series C - T3 Pharmaceuticals

boehringer-ingelheim-venture-fund_image

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund investment in Series B - T3 Pharmaceuticals

Reference-Capital-SA_image

Reference Capital SA

Reference Capital SA investment in Series B - T3 Pharmaceuticals

swiss-federal-commission-for-innovation-and-technology_image

Swiss Federal Commission for Innovation and Technology

Swiss Federal Commission for Innovation and Technology investment in Series A - T3 Pharmaceuticals

Official Site Inspections

http://www.t3pharma.com Semrush global rank: 11.21 M Semrush visits lastest month: 222

  • Host name: s007.cyon.net
  • IP address: 149.126.4.16
  • Location: Switzerland
  • Latitude: 47.1449
  • Longitude: 8.1551
  • Timezone: Europe/Zurich

Loading ...

More informations about "T3 Pharmaceuticals"

home - T3 Pharma

Developing the next generation bacterial cancer therapy. Click here for more on T3 Pharma's technology...See details»

T3 Pharmaceuticals - Crunchbase Company Profile

Organization. T3 Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. โ€ฆSee details»

T3 Pharma at a glance

The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for โ€ฆSee details»

T3 Pharmaceuticals AG โ€“ Swiss Biotech

Nov 22, 2023 The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments based on live bacteria. T3 Pharmaceuticals was acquired by Boehringer Ingelheim on 22 November 2023.See details»

T3 Pharmaceuticals AG - LinkedIn

Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments.See details»

Board of Directors - T3 Pharma

Lamine Mbow, PhD. Member of the Board of Directors. Lamine gained his PhD in immunology at the University of Neuchâtel, Switzerland, followed by postdoctoral training in host immunity at the CDC Fort Collins, CO and Colorado State โ€ฆSee details»

T3 Pharmaceuticals 2025 Company Profile: Valuation, Investors ...

T3 Pharmaceuticals General Information Description. Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery โ€ฆSee details»

Boehringer acquires T3 Pharma | Boehringer Ingelheim

Nov 22, 2023 Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 PharmaSee details»

T3 Pharmaceuticals AG - startup.ch

T3 Pharmaceuticals AG: The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company โ€ฆSee details»

T3 Pharmaceuticals AG

Explore T3 Pharmaceuticals AG with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 7 news, and 2 literature, Disease Domain:Neoplasms ...See details»

T3 Pharma - 2025 Company Profile, Funding & Competitors - Tracxn

Mar 23, 2025 T3 Pharma - Developer of novel and innovative medicines to treat cancer. Acquired by Boehringer Ingelheim. Raised a total funding of $42.7M over 3 rounds from 5 โ€ฆSee details»

T3 Pharmaceuticals - Overview, News & Competitors - ZoomInfo

T3 Pharmaceuticals contact info: Phone number: +41 612072074 Website: www.t3pharma.com What does T3 Pharmaceuticals do? T3 Pharmaceuticals is a pre-clinical biopharmaceutical โ€ฆSee details»

T3 Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The Org

View T3 Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»

T3 Pharmaceuticals Company Information - Funding, Investors, โ€ฆ

Website: https://t3pharma.com; Business model: b2b Company size: 1 - 11 employees Headquarters: Basel, Switzerland Social accounts: Linkedin; Funding. Funding series. Funding โ€ฆSee details»

T3 Pharmaceuticals acquired by Boehringer Ingelheim - Crunchbase

Nov 22, 2023 Acquiring Organization: Boehringer Ingelheim Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health. ...See details»

technology - T3 Pharma

T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria โ€ฆSee details»

T3 Pharmaceuticals - Craft

T3 Pharmaceuticals has 5 employees at their 1 location and $38.83 m in total funding,. See insights on T3 Pharmaceuticals including office locations, competitors, revenue, financials, โ€ฆSee details»

Boehringer buys cancer immunotherapy firm T3 for $507m

6 days ago Germanyโ€™s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.See details»

T3 Pharma acquired by Boehringer Ingelheim for up to 450M

Nov 22, 2023 Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharma โ€“ one of the first companies that BaseLaunch has financed โ€“ for an amount of up to โ€ฆSee details»

Boehringer Ingelheim acquires T3 Pharma for $509m

Nov 23, 2023 T3 Pharma will remain headquartered near Basel, Switzerland, with operations being kept in the region. As part of the acquisition, Boehringer Ingelheim will add T3 Pharmaโ€™s โ€ฆSee details»

linkstock.net © 2022. All rights reserved